Holistic Health Care P.Ltd
Holistic Health Care P.Ltd is situated in Secunderabad has largest chain of Ayurvedic wellness centers by the brand name of Ayu Care. Their Ayurvedic treatment include Pizhichil, Njavarakizhi, Abhyangam, Sirodhara, Vasthi, Sirovasthi and many more which rejuvenate your body and soul.

Arya Vaidya Sala, Kottakkal
Established way back 1902, Arya Vaidya Sala, Kottakkal’s one of the branches is situated in Secunderabad. It offers authentic Ayurvedic treatments therapies to patients all over India.

Kerala Ayur Kendra
Kerala Ayur Kendra in Secunderabad have highly qualified and experienced team of Ayurvedic physicians, both male and female. They have earned a reputation of being one of the leading panchkarma centers after their 45 years of service.

Pragati Sparsh
Sparsh of Pragati Resorts provide different types of massage therapies like sports massage, deep tissue massage, swedish massage and on-site chair massage. Each massage is designed for the needs of each client.

Saji D’Souza’s Kerala Sanjeevani Ayurvedic Center
Situated in West Hyderabad Saji D’Souza’s Kerala Sanjeevani Ayurvedic Center have a record of treating maximum number (16000) of patients in a short period of 7 years.

Latitudes Pro
Latitudes Pro with most experienced team in the fitness, Spa and Salon industries it can give you a whole personality change. Their facilities include Cardio Training, Strength Training, Personal Training, Group Exercises, Rock Climbing etc.

The Body Arena Gym
Established in 2002, The Body Arena Gym is a well ventilated spacious premises with a great variety of equipment. They have Experienced, Enthusiastic, Interactive and Dedicated trainers.

10-3-14/1, Sahara Complex,
Mehdipatnam,
Hyderabad – 500 028

Tel:+(91)-(40) – 55532280, 9246334794

Best Gym & Fitness Centre
Best Gym & Fitness Centre is one of the popular fitness centres in the city of Habsiguda and it is fully equipped with latest equipments.

Academy One / Ethno Fitness Centre
Academy One / Ethno Fitness Centre situated in West of Hyderabad is an exclusive health and fitness center where you can work out under the experienced supervision of their trainer.

The latest report from the European Centre for Disease Control and Prevention mentions that the fatality rate in the UK stands at 0.32 per cent. The UK has 12,470 confirmed hospitalised cases and 40 deaths. However, the case fatality rate — the number of deaths in proportion to the number of confirmed cases — remains in the same range as for seasonal flu, 0.1-0.35 per cent.

In the US, the number of hospitalised cases stands at 6,506 and the number of deaths (as on August 6) is 436, pegging the fatality rate at 0.67 per cent. The African region (which includes 16 countries) with 1,469 laboratory confirmed cases and three deaths has a fatality rate of 0.20 per cent. The East Mediterranean region has 2,532 confirmed cases and eight casualties. The fatality rate stands at 0.31 per cent. With 104 deaths and 13,169 confirmed cases, South East Asia has a 0.78 per cent fatality rate.

Experts believe that the number of fatalities will decline in the coming year. “H1N1 is a relatively new virus. The population will slowly develop immunity to it,” said Abhijit Das, Clinical Assistant Professor at Washington University. The virus gained ground in Mexico before spreading to other parts of the world. The US and the UK have witnessed swine flu deaths much before the virus started its death run in India. The country witnessed human-to-human transmission recently and suffered its first fatality in the beginning of August.

The Health Ministry’s decision to stop swine flu testing on every individual who

reports flu-like symptoms implies that the confirmed positive cases will now fall in the category of probable cases. “Hence, there will be an increase in the number of suspected H1N1 cases but as the population develops immunity to the virus, the death toll will decline,” said Rajib Dasgupta of the Centre for Social Medicine at Jawaharlal Nehru University.

As in other countries, the fatality rate in India will witness a decline in the months to come. “Global experience shows that just as the number of deaths were very rapid in other countries in the beginning and then slowly declined, in India too there will be a decline in the fatality rate in the next four months,” he added.

Meanwhile, India on Friday reported its 24th casualty due to the deadly H1N1 virus. Besides the 15 fatalities in Pune, two persons died in Mumbai and one each in Ahmedabad, Vadodara, Nashik, Thiruvananthapuram, Chennai, Bangalore and Raipur.

As many as 117 swine flu cases were reported from across the country, taking the total number of those afflicted by the virus to 1,390. Of the new cases, Mumbai reported the highest (29 cases), followed by Delhi and Hyderabad (13 each), Gujarat (10), Bangalore (9) and Kolkata (6).

Pune, which has been the worst affected, reported only four positive cases. All these cases are indigenous, with no foreign travel history. Of the 29 cases reported in Mumbai, 28 are indigenous while the remaining case was of a seven-year-old boy who travelled to the UK.

Thirteen cases have been reported from Delhi, of which 11 are indigenous. The two remaining cases are those of a 14-year-old boy with a travel history to Dubai and a 19-year-old who came from Israel. On the outskirts of the national Capital, Gurgaon reported five indigenous cases. Of the 13 cases from Hyderabad, two had travelled from Singapore, while all the 10 cases reported from Gujarat have no foreign travel history.

All the nine cases in Bangalore and six in Kolkata are indigenous. Two cases each were reported from Goa and Srinagar, while another is from Panchkula in Haryana. The virus has spared Assam so far. Of the 11 suspected cases, seven have tested negative. The results of the remaining four cases are awaited.

Recall a motion picture of 1970s. The villains would mist bullets during a hero, even chuck bombs during him, yet a favourite would come out unscathed. The hero, in turn, would glow in a air, a bullet would strike a flare post, rebound towards a knave as well as come in his skull. The favourite was indeed a superhero.

Welcome to a crazy, silly universe of QUICK GUN MURUGAN. In this film, a favourite as well as knave have been during loggerheads. The quarrel is in in in between vegetarian as well as non-vegetarian [meals]. Here, a knave wants to have a most appropriate dosa in locale as well as kidnaps women who have a undiluted recipe for creation tasty dosas.

QUICK GUN MURUGAN is not a stereotypical movie, yet it borrows from all stereotypical motion picture that done Indian motion picture so graphic from rest of a world. The most appropriate partial is, QUICK GUN MURUGAN is innovative.

One judgment verdict? Try this dosa… it’s delicious!

Quick Gun Murugun [Dr. Rajendra Prasad] is an doubtful superhero. He is a frank South Indian cowboy who considers it his avocation to offer as well as protect. The movie revolves around a misadventures of Quick Gun Murugun as well as his quarrel with his physical condition knave Rice Plate Reddy [Nasser].

Quick Gun Murugun enters in to an epic conflict that spans time as well as space, from a tiny South Indian encampment to Swarglok as well as afterwards eventually to a worldly Mumbai. He is ripped in in in between Mango Dolly [Rambha], who loves him as well as his initial adore Locket Girl [Anu Menon] as well as his faithfulness is put to a test.

QUICK GUN MURUGAN depicts a fight in in in between great as well as immorality as well as what creates it a novel knowledge is that a characters have been true out of 1970s. Director Shashanka Ghosh’s preference of a theme as additionally a execution deserves credit.

But there’s a hitch. There’s as well most Tamil in a film, that yet explained by sub-titles, might infer a halt in non-Tamil areas. In fact, a South Indian interest would shorten a invasion in to a indentation as well as dilemma of a country.

Dr. Rajendra Prasad as well as Nasser strive for tip honours. Both excel. Rambha suits a role. Anu Menon is good. Raju Sundaram does a excellent job. Vinay Pathak has a short role. Ditto for Ranvir Shorey, Gaurav Kapur as well as Sandhya Mridul. Ashwin Mushran is first-rate. Kishori Balla [Anni] is perfect.

On a whole, QUICK GUN MURUGAN is an innovative experience. The adventures should interest to a girl mainly.

Rate this:

Choreographer incited filmmaker Farah Khan is perplexing to overpass a opening in in in between dual Bollywood stars, Shahrukh Khan as well as Salman Khan. She thinks which a quarrel in in in between a dual is stretching as well prolonged as well as they should finish up quarrel as well as turn friends now. “I instruct you could overpass a gap. you adore both of them. It’s (the fight) removing longer now,” Farah told

Farah Khan who hosts a important radio discuss show, ‘Tere Mere Beech Mein’ has invited Salman Khan as well as his mom Salma Khan in a starting part as well as she feels similar to to finish a uncover with her tighten crony Shahrukh Khan. “Since Salman had never come upon a discuss uncover prior to as well as was really vehement during a show, you done him a initial guest. But Shahrukh will be a final a single to keep a assembly bending compartment a end,” she says.

Farah is tighten to both a rivals, Shahrukh as well as Salman, professionally as well as personally. On veteran front, if she has done movie with Shahrukh Khan ‘Om Shanti Om’ afterwards she had choreographed a strain of Salman’s arriving movie ‘Mr as well as Mrs Khanna’.

Farah wants to fool around dove in in in between a dual friends incited foe.

It is not a nice way to die. As the virus spreads through your lungs, your immune system goes into overdrive. Your lungs become leaky and fill with fluid. Your lips and nails, then your skin, turn blue as you struggle to get enough oxygen. Basically, you drown.

Of course, most flu strains, including (so far) the 2009 pandemic virus, cause only mild symptoms in the vast majority of people. But with 10 to 20 per cent of people worldwide contracting the flu every year, that still adds up to a huge burden of illness – and even in a good year some half a million die.

What if it need not be this way? If only we could develop a vaccine that was effective against all strains of flu, we might prevent both annual epidemics and occasional pandemics like the one now under way.

Recent work suggests it is possible to create just such a vaccine. In fact, the effectiveness of one potential universal vaccine will be tested in people for the first time in September. Could we be on the brink of beating flu?

The reason flu keeps infecting us again and again is that the virus is constantly changing. The first time you get infected, your immune system has to rely initially on innate, non-specific defences. But it also evolves specific defences, learning to make antibodies and immune cells that recognise that particular virus and destroy both it and any cells it has infected. This process can take a week or more, but once we have defences against a virus, we can respond to it quickly next time. This is why many viruses, such as measles, make us ill only once

Flu viruses, however, evolve so fast that this “immune memory” provides only partial protection. Most of the antibodies we produce bind to the globular heads of a surface protein on the virus called haemagglutinin. The next big target is another surface protein, called neuraminidase.

By staying one step ahead of our immune systems, the flu virus can infect large numbers of people year after year. What’s more, every few decades a flu strain acquires a new haemagglutinin – by swapping genes with a pig or bird flu strain, say – that is very different from those most people have immunity to, so we have very little protection. This is when flu goes pandemic.

Existing flu vaccines all work by mimicking natural infections. Based on monitoring of flu strains, virologists try to predict which haemagglutinin and neuraminidase will dominate during the next flu season. The annual vaccines contain inactivated flu viruses bearing these specific proteins. If the virologists guess right, the vaccine will protect you until the virus changes enough again.

There is, however, a flaw in the whole idea. “Haemagglutinin’s a decoy,” says Wayne Marasco, an immunologist at Harvard Medical School in Boston. Like a bullfighter’s cape, in other words, the heads of haemagglutinin deflect the immune attack away from more vulnerable parts of the virus.

To refocus the immune attack, the idea is to create vaccines containing only the conserved proteins, rather than whole viruses. Most attention has focused on the M2 protein that protrudes from the virus’s surface and tells it when it is inside a cell. At least 10 companies have been looking into vaccines that provoke a reaction to the protruding part of M2, a piece called M2e. Pure M2e does not elicit strong immune reactions when injected as a vaccine, so all groups have attached M2e to molecules that do provoke a strong response.

Three companies have got as far as human trials. Merck bound M2e to a bacterial protein, but people injected with this hybrid made antibodies only when the vaccine also contained an extra immune stimulator, or adjuvant, in quantities that caused pain on injection. Merck abandoned the project in 2007.

Acambis of Cambridge, UK, has coupled M2e molecules to a fragment of hepatitis virus to get the immune system’s attention. In 2008, it reported that when mixed with two adjuvants, 90 per cent of people made antibodies and had no severe side effects. It also protected 70 per cent of ferrets, the best test animal for flu, from H5N1 bird flu. However, work has slowed as Acambis is absorbed by a new owner, the French vaccine giant Sanofi-Pasteur.

VaxInnate, a small biotech firm in Cranbury, New Jersey, has engineered a hybrid protein containing four copies of M2e bound to flagellin, a building block of bacteria. “We got the same antibody reaction as the others, without the adjuvant,” says the head of the company, Alan Shaw, former head of public health at Merck.

There is, however, a big difference between showing that a vaccine is safe and stimulates antibody production, and showing it protects people from flu. VaxInnate is planning further trials, but these are on hold as health authorities deal with swine flu.

Sarah Gilbert at the University of Oxford and colleagues have taken a different approach. They have modified a virus called MVA, a variety of the virus used for decades as a smallpox vaccine, to produce the entire M2 protein. Dr Gilbert’s aim with this live vaccine is to stimulate white blood cells called T-cells to get so-called cell-mediated immunity, not so much to induce antibodies.

Work to be published soon, by John Oxford of Barts and the London School of Medicine and Dentistry, shows that infected volunteers with high cell-mediated immunity get few or no flu symptoms.

“T-cells certainly limit the severity of disease,” he says. “But I’d love to test a vaccine that induces antibodies to M2e too.”

Dr Oxford is a director of RetroScreen Virology, a company with the only facility in the world where people can be experimentally exposed to flu. RetroScreen will be testing Dr Gilbert’s vaccine this September – the first-ever trials designed to see if a potential universal flu vaccine can prevent infection or reduce disease severity. If tests are successful, the vaccine might be approved within three years.

An effective universal vaccine that is cheap enough to be widely used could even eliminate annual flu epidemics and the occasional pandemics. That is a huge prize, one you might think that countries and researchers around the world would be working together to achieve.

It is indeed ironical that Pune, the epicenter of swine flu, which has claimed 12 of the 24 deaths in India, out of the 1,390 confirmed cases, and from where the first victim in the country was reported, also happens to be home to one of the world’s largest biotech companies developing a vaccine to fight the Influenza A H1N1 virus.

A team of 25 scientists are racing against time as part of the global battle to develop the vaccine against the spread of dreaded disease. “The vaccine sample is ready and we will begin animal trials by next month (September) in Holland. The phase I of human clinical trials will begin by December-January and subsequently, phase II and phase III trials will be carried out”, said Suresh S Jadhav, executive director of Serum Institute of India, the flagship company of the Poonawalla Group.

No vaccine is yet available available anywhere in the world for the H1N1 virus. The earliest batch could become available in the US by September or October this year. After the successful human clinical trials, Jadav the Institue would seek government regulatory approvals. “If everything goes as planned, the commercial production of the vaccine may begin by March-April 2010”, Jadhav said, adding that the process was time consuming and the company would not compromise on following global standards in manufacturing the eagerly-awaited vaccine. The Institute is one of 21 worldwide asked by WHO to produce the vaccine. It’s the only one in India.

The advisory committee on immunisation practices at the US Centers for Disease Control has recommended the order in which vaccines should be given: pregnant women; household contacts and caregivers for children less than six months of age; healthcare and emergency medical services personnel; all people from six months through 24 years of age; persons aged 25 through 64 years who have health conditions associated with higher risk of medical complications; all others in the same age-group and people above 64. The last group is supposed to still have some immunity from the influenza A pandemic in 1968 and is supposed to be least at risk.

Till August 14, WHO regions reported 177,457 laboratory-confirmed cases of new-H1N1 influenza virus with 1,462 deaths. The H1N1 strain has become the dominant inlfuenza virus in the world, comprising 71 per cent of all such cased detected globally. Some scientists say that H1N1 incidence will rise sharply in October-November, mimicking the seasonal flu which has a low impact in summer months.

Akhilesh Chandra Mishra, director of National Institute of Virology, said the virus was spreading rapidly but the government health machinery all over India has been geared up to tackle the pandemic. “All the 17 regional laboratories in the country have been upgraded and provided with reagents and machinery to work as H1N1 testing centers,” he said. Mishra said a second wave of the swine flu could not be predicted accurately. “It may be milder or stronger and there are chances that there may not be a second wave at all,” he said.

Although the H1N1 flu entered India late, it has spread like a bush fire. The first deaths created a wave of panic with state governments shutting schools, malls and movie theatres. The price of a simple face mask rose from Rs 5 to Rs 150 in some cities. Even though the number affected in the country is increasing, the fact is that the total number of people that swine flu has killed worldwide is lower than the number of Indians who die in a single day from tuberculosis and diarrhea-related diseases. Jai Narain, head of the regional communicable disease office for WHO told media that “the amount of frenzy or hysteria is totally disproportionate to the overall reality of the disease.”

Much of the public’s concern may be alleviated if the vaccine is available. Hyderabad-based Bharat Biotech International, Panacea Biotec in New Delhi and Cadila Pharmaceutical in Ahmedabad are also in the race to develop the vaccine. “On August 18, we are meeting top Drug Controller General of India and Indian Council of Medical Research officials to speed up work on developing the vaccine in New Delhi,” said Krishna Ella, founder chairman and managing director of Bharat Biotech. The company is a WHO pre-qualified manufacturer of hepatitis B and other vaccines for supply to Unicef. He said about 40 scientists were engaged day and night at the company labs and human clinical trials to develop the vaccine would start by October.

Rajesh Jain, joint managing director of Panacea Biotec, said the firm was readying its manufacturing plant at Lalru, near Chandigarh, for mass production of the vaccine. Panacea Biotec is the second largest vaccine player in India. It has WHO pre-qualification for pentavalent vaccine, Oral Polio Vaccine, and hepatitis B vaccine. “There will be a huge demand which can be gauged by the extent of the spread of the disease in India and the world”, Jain said, adding it was not possible to give the time-line for manufacturing the vaccine.

Apart from the vaccine, Oselta-mivir or Tamiflu is the medicine reported to be effective against swine flu strain if taken within the first 48 hours of catching the virus. In response to the outbreak, the Indian government has set up testing centers around the country and asked drug firms such as Ranbaxy, Hetero, Natco Pharmaceuticals, Cipla and Strides Arcolab to stock about 7.2 million Oseltamivir tablets to handle any emergency situation. This would be apart from the 30 million doses that the government would stock. “We are in constant touch with drug companies and they would be able to supply enough drugs to the government by next week,” Vineet Chaudhry, joint secretary at the health ministry said.
The health ministry has allowed, among others, Super Religare Laboratories, Dr Lal PathLabs, Metropolis Health Service and Quest Diagnostics to import test kits for H1N1. “The ministry has decided to import another 22,000 kits at a cost of Rs 1.75 crore,” V M Katoch, director-general of Indian Council of Medical Research, said. That’s apart from the 27,000 imported earlier. Arvind Lal, chairman and managing director of Dr Lal PathLabs, said, “We will import kits… But we already have the real-time polymerase chain reaction and other facilities to test swine flu because the same technology is used to test HIV, Hepatitis B and genotyping of TB.” A senior health ministry official said the process to approve private labs has been started. At present, each test costs Rs 5,000, while a positive case costs Rs 10,000, since the test has to be repeated. Government hospitals provide this facility free. Private labs and hospitals would charge its patients. Most states are also naming additional hospitals, including private ones, which can treat swine flupatients. Delhi has identified 13 hospitals.

Preparation and precautions are necessary as WHO has termed the virus unstoppable. Aided by frequent flyers, it has spread to 163 countries in nine weeks, compared with earlier influenza viruses, which took an average of 25 months to distribute globally. The summer in the northern hemisphere is the time when influenza viruses normally lie low, waiting for their turn to strike as the winter sets in. Hopefully, the combination of steps taken by the state and central government would be able to contain the virus from doing too much damage.

Mumbai: Hyundai Motor Company, the Korean carmaker, will start its Hyderabad research & development facility in September to cater to its future models and also those of its sister concern, Kia Motors.

H S Lheem, managing director, Hyundai Motor India, said, “We have invested $40 million in this facility and 210 Indian and 10 Korean engineers are working with us. This number will go up to 800-1,000 Indian engineers within five years.”

The company also plans to launch Santa Fe, its sports utility vehicle (SUV), by the end next year. “Santa Fe will be in completely knocked down (CKD) form with localisation of 30%. It is viable to get it as a CKD instead of a completely built unit (CBU) as the import duty is 60% while that on components is only 10%. From India we will look at components such as glass, seats, tyre etc,” Lheem said.

Hyundai is also developing an 800cc engine for its car which will be smaller than Santro. “The engine will be developed in Korea and the production will take place in India. This car will compete against WagonR.”

The launch, however, will take another couple of years, Lheem said. He did not divulge pricing details for both the SUV and the small car. For its i10 and i20 models, Hyundai is developing a diesel engine of 1.1-1.5 litre capacity in Korea and is awaiting an approval from the parent company. The engine will take 2-3 years to be developed, Lheem said.

Also, the company plans to raise its sales in the overseas market this year.